FDCP
TEVA icon

Foster Dykema Cabot & Partners’s Teva Pharmaceutical Industries Limited TEVA Stock Holding History

Foster Dykema Cabot & Partners’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-33
Closed -$595 – 480
2024
Q3 		$595 Hold
33
– – ﹤0.01% 489
2024
Q2 		$536 Buy
+33
New +$508 ﹤0.01% 313

Other funds holding TEVA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return
IAM
Ion Asset Management Herzliya, Israel $911M AUM 24.97% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $25.6B AUM 50.04% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $15.6B AUM 71.29% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $14.6B AUM 57.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

Foster Dykema Cabot & Partners's TEVA Position: Q4 2024 in Review

Foster Dykema Cabot & Partners sold out of Teva Pharmaceutical Industries Limited (TEVA) in Q4 2024, closing a stake of 33 shares — an estimated $595 sold.

Foster Dykema Cabot & Partners first reported a position in TEVA in Q2 2024 and held it in 2 quarters. The position peaked at $595 in Q3 2024. 584 funds tracked by Wall St. Rank hold TEVA as of Q4 2024.

  • Foster Dykema Cabot & Partners reported no remaining Teva Pharmaceutical Industries Limited position as of Q4 2024 after selling out during the quarter.
  • Foster Dykema Cabot & Partners sold 33 Teva Pharmaceutical Industries Limited shares in Q4 2024, an estimated $595.
  • Foster Dykema Cabot & Partners first reported a position in Teva Pharmaceutical Industries Limited in Q2 2024 and held it in 2 quarters.
  • Foster Dykema Cabot & Partners's Teva Pharmaceutical Industries Limited position peaked at $595 in Q3 2024.
  • 584 funds tracked by Wall St. Rank held Teva Pharmaceutical Industries Limited as of Q4 2024.

Based on Foster Dykema Cabot & Partners's 13F filing for Q4 2024, filed 13 Feb 2025.